Clear cell renal cell carcinoma, the most common form of kidney cancer, is usually linked to inactivation of the pVHL tumour suppressor protein and consequent accumulation of the HIF-2α transcription factor (also known as EPAS1)
Letter reSeArCH HIF-2α from binding to ARNT (Fig. 1b and Extended Data Fig. 1c ) and hence to DNA [2] [3] [4] [5] [6] . PT2399 minimally affected a panel of 68 receptors, ion channels, and enzymes (Supplementary Table 4) .
Treating VHL −/− 786-O clear cell renal cell carcinoma (ccRCC) cells with PT2399 repressed various HIF target genes in mRNA microarray (Fig. 1c) , real-time PCR (Fig. 1e, f and Extended Data Fig. 1d ), immunoblot ( Fig. 1g) and ELISA (Fig. 1h) assays. PT2399 did not suppress HIF-1α -specific targets such as BNIP3 (Fig. 1e and Extended Data Fig. 1e ). As well as binding directly to HIF-2α , PT2399 destabilized HIF-2α , which might enhance the effects of PT2399 on the DNA-binding activity of HIF-2α (Fig. 1e, g and Extended Data Fig. 1f ). PT2399 downregulated gene sets that were induced by hypoxia, HIF, and c-Myc, consistent with reports that HIF-2α and c-Myc cooperate to promote ccRCC 7, 8 (Fig. 1d , Extended Data Fig. 1g and Supplementary Table 5) .
Next we made HIF-2α −/− 786-O cells using the CRISPR-Cas9 gene editing technique (Extended Data Fig. 2a ). The cells proliferated under standard conditions (Extended Data Fig. 2c-f) , consistent with the effects of suppression of HIF-2α by short hairpin (sh)RNA and treatment with pVHL in 786-O cells 9, 10 . We then used a lentivirus to reintroduce wild-type HIF-2α or a HIF-2α missense mutant (S304M) with an occluded PT2399-binding pocket 4 into these cells (Fig. 2a) . The effects of PT2399 on HIF-responsive mRNAs was largely eliminated in cells lacking HIF-2α (Fig. 1c, d ) or expressing HIF-2α S304M (Fig. 2b) .
PT2399 (up to 2 μ M) minimally altered ccRCC cell line proliferation under standard cell culture conditions (Extended Data Fig. 2c, g-j) . Fig. 3a, f) . This effect was specific because it was reversed by expression of HIF-2α S304M (Fig. 2d, g ) and not seen in VHL +/+ SLR21 ccRCC cells (Extended Data Fig. 3c, f) . Similarly, HIF-2α −/− 786-O cells did not form soft agar colonies unless rescued with exogenous HIF-2α (Fig. 2e-g and Extended Data Fig. 2b ). Therefore, PT2399 decreases HIF-dependent transcription and soft agar growth in an on-target manner.
As a step towards imaging studies we infected 786-O cells, as well as isogenic cells expressing exogenous pVHL, with a lentivirus encoding firefly luciferase (Luc) driven by a HIF-responsive promoter (3 × HRELuc). As expected, PT2399 inhibited Luc activity in the VHL −/− cells but not in their pVHL-proficient counterparts (Fig. 3a, b) . Conversely, the diooxygenase inhibitor dimethyloxaloylglycine (DMOG), which blocks the binding of pVHL to HIFα , induced Luc activity in the pVHL-proficient cells but not in the VHL −/− cells (Fig. 3a) . As expected, PT2399 did not affect Luc driven by constitutive promoters, such as the CMV promoter (Fig. 3c) .
Next, 3 × HRE-Luc 786-O cells and CMV-Luc 786-O cells were injected into opposing kidneys of nude mice. Once tumours were established, as determined by serial bioluminescence imaging (BLI), the mice were given PT2399 or vehicle twice daily (Extended Data Fig. 1h, i) . Two days of treatment with PT2399 decreased the 3 × HRELuc signal by more than 60%, similar to its effects in vitro (Fig. 3d, f) . These effects were not observed in the CMV-Luc tumours or in vehicle-treated mice (Fig. 3d, e) . In PT2399-treated mice, the 3 × HRE-Luc signal recovered after a drug washout period and HIF-2α S304M −/− cells (sgHIF-2α #6) were superinfected with a lentivirus encoding an sgRNA-resistant HIF-2α cDNA (HIF-2α ) or with the empty vector (EV). g, Quantification of soft agar colony formation in c-f. n = 3 biological replicates. Data shown as mean ± s.e.m. * P < 0.05, * * P < 0.01 and * * * P < 0.001 by two-tailed Student's t-tests (b, g). NS, P > 0.05.
Letter reSeArCH decreased again after drug rechallenge (Fig. 3g) . Analysis of kidneys removed after 2 days of PT2399 treatment revealed decreased HIFresponsive mRNAs, decreased Ki-67 staining (representing decreased proliferation), increased caspase 3 cleavage (reflective of increased apoptosis) and decreased microvessel density (Extended Data Fig. 4a-e) .
To assess the antitumour efficacy of PT2399, CMV-Luc 786-O cells were grown orthotopically in nude mice; once tumours were established, the mice were treated with PT2399 or vehicle. As expected, tumours continued to grow in vehicle-treated mice, as shown by weekly BLI. In contrast, PT2399 caused tumour stasis or regression (Fig. 4a-c and Extended Data Fig. 4f ), which correlated with decreased circulating tumour-derived VEGF (Extended Data Fig. 4g ), decreased proliferation and decreased angiogenesis (Extended Data Fig. 4h ).
Kidney-confined ccRCC can often be treated surgically. We therefore obtained a metastatic variant of 786-O cells (M2A cells) expressing Luc under an HSV TK promoter; these cells form diffuse lung colonies after tail vein injection 11 . In this model, PT2399 still caused marked tumour regression and prolonged survival (Fig. 4d-f) . Similar results were obtained when a limited number of cells were injected in an effort to better mimic established lung metastases (Extended Data Fig. 5a, b) . Introducing HIF-2α S304M into M2A cells (Fig. 4g ) conferred partial resistance to the pharmacodynamic (Extended Data Fig. 5c ) and antitumour effects of PT2399 (Fig. 4h, i) .
PT2399 also inhibited the growth of VHL −/− A498 ccRCC cells in soft agar and orthotopic tumour assays (Extended Data Fig. 3b, f and Extended Data Fig. 6 ), consistent with the effects of HIF-2α shRNA in these cells 10 , and inhibited the growth of a VHL −/− ccRCC patient-derived xenograft (PDX) (Extended Data Fig. 5d, e) . By contrast, PT2399 did not suppress orthotopic tumours formed by VHL −/− UMRC-2 cells or VHL −/− 769-P ccRCC cells (Fig. 5a-d ) despite inhibiting HIF-2α dimerization and HIF-2α -dependent transcription in these cells with IC 50 s comparable to those seen in 786-O and A498 cells (Fig. 1b and Extended Data Fig. 7a-d) and despite effective suppression of HIF target genes in vivo (Extended Data Fig. 8a ).
To study this differential sensitivity further, we measured HIF-2α abundance and the response of selected HIF target genes to PT2399 and to pVHL across a panel of VHL −/− ccRCC cell lines. The PT2399-sensitive 786-O and A498 cells had higher HIF-2α levels than the insensitive UMRC-2 and 769-P cells (Fig. 5e) . The PT2399-sensitive cells also exhibited greater inhibition of HIF target genes, as a percentage of basal expression, in response to PT2399 (Fig. 5f and Extended Data Fig. 8d, e) and, where tested, pVHL (Extended Data Fig. 8b, c) . The latter finding further supported the idea that this differential sensitivity to PT2399 reflects differences in HIF-2α dependence rather than differences in intracellular drug accumulation. Indeed, growth of UMRC-2 cells and 769-P cells in soft agar was insensitive to Cas9-mediated inactivation of HIF-2α and to PT2399, unlike growth of 786-O and A498 cells (Fig. 5g-j and Extended Data Fig. 3c, f, g ). Similarly, growth of VHL −/− SKRC-20 and UMRC-6 ccRCC cells in soft agar was unaffected by genetic disruption of HIF-2α or treatment with PT2399 (Extended Data Fig. 3c-g ). Growth of RCC10 cells in soft agar was unaffected by PT2399, but was suppressed in an on-target manner by Cas9-mediated loss of HIF-2α , despite the cells showing a similar decrease in HIF-2 target mRNAs in response to both (Extended Data Fig. 3c-g and Extended Data Fig. 9a-f) . The importance of this discrepancy is unclear because the HIF-2α −/− RCC10 cells quickly regained the ability to grow in soft agar after repeated culture despite persistent HIF-2α loss (see also below). Finally, we confirmed that genetic disruption of HIF-2α , like treatment with PT2399, did not affect orthotopic tumour growth by UMRC-2 cells (Extended Data Fig. 10 ).
Differential HIF-2α dependence amongst ccRCC lines is not linked to their HIF-1α status because the insensitive cell lines 769-P and SKRC-20, like the sensitive cell lines 786-O and A498, lack wild-type HIF-1α 12 . Moreover, Cas9-mediated ablation of HIF-1α in UMRC-2 cells did not render them HIF-2α -dependent in soft agar assays (Extended Data Fig. 7e-g ). 
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By contrast, HIF-2α dependence across the ccRCC lines we examined loosely correlated with their basal HIF-2α levels and the dependence of HIF target genes in those lines on HIF-2α itself. A caveat is that some of these lines might have lost their dependence on HIF-2α owing to prolonged passage in culture, especially as HIF-2α is not required under standard culture conditions. On the other hand, freshly explanted ccRCC PDXs also show variable sensitivity to PT2399 (ref. 13) .
To begin to understand this differential HIF-2α dependence further, we focused on RCC10 cells because HIF target genes and soft agar growth are less dependent on HIF-2α in these cells than in 786-O and A498 cells despite their comparably high HIF-2α levels ( Fig. 5e and Extended Data Figs 3c-g, 9b) . We discovered that RCC10 cells harbour the canonical p53 R248W mutant (Extended Data Fig. 9g ). The p53 R248W mutation also arose spontaneously in a 786-O subclone made in our laboratory (Extended Data Fig. 9h ) and was associated with acquired resistance to PT2399 (Extended Data Fig. 9i) . p53 was not induced by DNA damage in the HIF-2-independent lines UMRC-2 and 769-P, suggesting that these cells also have p53 pathway mutations, but was induced in the HIF-2-independent lines UMRC-6 and Caki-2 (Extended Data Fig. 9g, j) . Of note, p53 was modestly induced by PT2399 and Cas9-mediated loss of HIF-2α in p53 +/+ 786-O cells (Extended Data Fig. 9h, k) , consistent with reports that HIF-2α constrains p53 activity in ccRCC 14, 15 . Therefore an intact p53 pathway seems necessary, but not sufficient, for HIF-2-dependence in ccRCC.
Our findings suggest that the response of VHL −/− ccRCC to HIF-2α antagonists will be variable and that predictive biomarkers, perhaps including measures of HIF-2α activity and p53 status, will be needed. The current view that p53 mutations are uncommon in ccRCC is based mainly on studies of primary tumours removed at nephrectomy 1 . p53 pathway mutations might be more common in metastatic ccRCC, from which most ccRCC lines are derived, or might arise after ccRCC therapies 16 . Alternatively, some p53 mutations in ccRCC lines might have arisen ex vivo. Another important question is whether adding HIF-2α antagonists will enhance the activity of existing ccRCC drugs. e, f, Quantification of BLI values (e) and Kaplan-Meier survival curves (f) from mice treated as in d (vehicle, n = 9 mice from two independent experiments; PT2399, n = 9 mice from two independent experiments). g, Immunoblots of M2A cells infected with a lentivirus encoding HIF-2α S304M or empty vector (EV). h, Representative BLI of lung colonies formed by M2A cells in g treated with PT2399 (30 mg kg −1 ) or vehicle twice daily by oral gavage (for empty vector, n = 7 vehicle-treated and n = 8 PT2399-treated; for S304M, n = 9 vehicle-treated and n = 10 PT2399-treated) from two independent experiments. i, Quantification of BLI values as in h. Data shown as median with range (c, e, i). Statistical significance was assessed using Mann-Whitney test (c and i), unpaired t-test (e) or log-rank test (f).
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